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Summary
Prenatal diagnosis aims either to provide the reassur-
ance to the couples at risk of having an affected child 
by timely appropriate therapy or to give the parents 
a chance to decide the fate of the unborn babies with 
health problems. Invasive prenatal diagnosis (IPD) is 
accurate, however, carrying a risk of miscarriage. Non-
invasive prenatal diagnosis (NIPD) has been developed 
based on the existing of fetal genetic materials in mater-
nal circulation; however, a minority fetal DNA in major-
ity maternal background DNA hinders the detections of 
fetal traits. Different protocols and assays, such as ho-
mogenous MassEXTEND (hME), single allele base exten-
sion reaction (SABER), precise measuring copy number 
variation of each allele, and quantitative methylation and 
expression analysis using the high-throughput sensitive 
matrix-assisted laser desorption/ionization-time of flight 
mass spectrometry (MALDI-TOF MS), allow NIPD for sin-
gle gene disorders, fetal blood group genotyping and 
fetal aneuploidies as well as the development of fetal 
gender-independent biomarkers in maternal circulation 
for management of pathological pregnancies. In this re-
view, we summarise the use of MALDI-TOF MS in prena-
tal genomics.
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Zusamenfassung
Die pränatale Diagnostik zielt darauf ab, entweder Paa-
ren, bei denen das Risiko eines betroffenen Kindes be-
steht, die Rückversicherung für eine rechtzeitige ange-
messene Therapie zu geben, oder Eltern die Chance zu 
geben über das Schicksal von ungeborenen Kindern mit 
schwerwiegenden gesundheitlichen Einschränkungen 
zu entscheiden. Die invasive pränatale Diagnostik (IPD) 
ist präzise, birgt aber das Risiko einer Fehlgeburt. Die 
noninvasive pränatale Diagnostik (NIPD) wurde auf der 
Grundlage des vorhandenen fetalen genetischen Mate-
rials im mütterlichen Blutkreislauf entwickelt. Allerdings 
erschwert die geringe Menge fetaler DNA innerhalb der 
großen Menge an mütterlicher DNA den Nachweis von 
fetalen Charakteristika. Verschiedene Protokolle und As-
says – z.B. «homogenous MassEXTEND» (hME), «single 
allele base extension reaction» (SABER), präzise Mes-
sung der Variation der Kopienzahl eines jeden Allels 
und quantitiative Methylierung und Expressionsanalyse 
mithilfe der «matrix-assisted laser desorption/ioniza-
tion-time of flight mass spectrometry» (MALDI-TOF MS) 
– ermöglichen eine NIPD von einzelnen Genstörungen, 
fetaler Blutgruppengenotypisierung und fetalen Aneu-
ploidien ebenso wie die Entwicklung von fetalen, ge-
schlechtsunabhängigen Biomarkern in der mütterlichen 
Zirkulation für das Management pathologischer Schwan-
gerschaften. Die vorliegende Arbeit gibt einen Überblick 
zur Verwendung von MALDI-TOF MS in der pränatalen 
Diagnostik.
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Introduction 
Approximately 2–4 out of 100 babies have birth defects de-
fined as abnormalities of structure, function or body metabo-
lism, which is a serious and costly public health problem as 
well as a family problem when combining medical and social 
factors [1, 2]. A routine prenatal diagnostic test to detect birth 
defects in the fetus or embryo before it is born has been intro-
duced for either performing a timely appropriate treatment or 
giving the parents a chance to decide the fate of the unborn 
babies with health problems [3, 4]. The most common indica-
tion for prenatal diagnosis is advanced maternal age at risk of 
having babies with chromosome abnormalities [5, 6]. The mo-
nogenic disorders are also a common reason why couples opt 
for prenatal genetic testing [7]. Conventional methods for pre-
natal genetic testing are based on invasive procedures, such 
as chorionic villus sampling, amniocentesis and cord blood 
sampling, to obtain fetal genetic materials for prenatal genetic 
analysis [8, 9]. The invasive procedures involve needles being 
inserted into the placenta or cord, which is associated with 
a risk of miscarriage to the fetus, thus, resulting in physical 
and mental burden to the affected pregnant women as well 
as their family members [10–14]. Because of this, many medi-
cal scientists made efforts to move toward less invasive pro-
cedures for prenatal diagnosis. Several non-invasive screen-
ing methods, such as ultrasonography and maternal serum 
screen, have been developed to evaluate the risk of carrying 
an aneuploidic fetus; however, a final definitive diagnosis re-
garding the pathological factor cannot be made through those 
non-invasive screen approaches [15, 16]. Additionally, those 
approaches are not useful for the prenatal diagnosis of fetal 
monogenic disorders [17–20]. 
Risk-Free Non-Invasive Prenatal Diagnosis 
The discovery of fetal cells in the maternal circulation seemed 
to offer a new opportunity for a risk-free, non-invasive pre-
natal diagnosis (NIPD) [21]. The advantage of fetal cells in 
maternal blood for analysis of chromosome abnormalities is 
that fetal cells have complete fetal genetic features [22]. Sev-
eral fetal cell types, such as fetal leucocytes, fetal nucleated 
red blood cells (erythroblasts) and placental trophoblasts, 
have been found in maternal circulation and were suggested 
as a potential source of fetal genetic materials for prenatal 
diagnosis obtainable from maternal blood [23]. Due to the 
limited lifespan and relative higher frequency of fetal erythro-
blasts in the fetus in early gestation, this type of cells has been 
mostly studied for NIPD [24, 25]. Scientists attempted in the 
past decades to isolate fetal erythroblasts from maternal cir-
culation for prenatal diagnosis using different methods, such 
as fluorescence-activated cell sorting(FACS)-based positive 
selection and magnetic-activated cell sorting(MACS)-based 
positive selection; however, the isolation procedures were 
tedious to perform, and a significant proportion of enriched 
erythroblasts were of maternal origin [26, 27]. In addition, 
rare fetal cells, mostly with apoptotic properties circulating in 
maternal blood, have made genetic analysis difficult and clini-
cal application unavailable [28]. 
The discovery of circulating cell-free fetal DNA (cff-DNA) 
in maternal plasma has opened new opportunities for NIPD 
[29]. Compared to fetal cells in maternal circulation, cff-DNA 
in maternal plasma could be detected earlier, more frequent-
ly, and in greater amounts than the cellular species [30–33]. 
The clearance of cff-DNA in maternal circulation is very 
rapid [34], and therefore it is a suitable target for prenatal 
diagnosis without being biased by any previous pregnancies. 
Fetal genetic materials in maternal circulation, such as the 
fetal sex determining region of Y (SRY) and the fetal RhD in 
the circulation of RhD-negative pregnant women [35], which 
are absent from the maternal genome, can be easily deter-
mined using real-time PCR. Risk-free prenatal identification 
of fetal gender regarding X-linked disorders and fetal RhD 
status for the management of RhD-negative pregnant women 
using cff-DNA has been successfully applied for clinical use 
[36, 37]. However, the fact that cff-DNA circulating in mater-
nal plasma is a minor component within the total DNA being 
released from maternal blood cells makes the prenatal diag-
nosis of fetal chromosome abnormalities crucially difficult [38, 
39]. Paternal inherited monogenic disorders with subtle muta-
tions in minor fetal components, which only differ slightly in 
the predominated maternal wild-type DNA of interest, also 
offers a considerable challenge for NIPD using cff-DNA in 
maternal circulation [40]. A precise quantitative and qualita-
tive molecular biological technique using fetal genetic materi-
als circulating in maternal blood seems to be in demand for 
sensitively and specifically detecting fetal single nucleotide 
polymorphism (SNP) as well as fetal trisomy. 
MALDI-TOF MS
Matrix-assisted laser desorption/ionization-time of flight mass 
spectrometry (MALDI-TOF MS) was initially developed for 
the application in the analysis of proteins and peptides. Later 
this technology found its great use for sequence variation 
analysis in the post-genome sequencing era [41, 42]. Based 
on this platform, Sequenom (San Diego, CA, USA) initiated 
a company for developing high-throughput qualitative and 
quantitative analysis of SNPs through an accurate and direct 
measurement of the molecular weights of the nucleic acid 
products, at about 100 times higher resolution than capillary 
sequencing [43, 44]. The approach combines PCR, base exten-
sion reaction and MALDI-TOF MS analysis. The DNA se-
quence of interest is amplified by PCR. An extension primer 
designed by homogenous MassEXTEND (hME) software 
adds to the extension reaction. DNA polymerase along with 
a mixture of terminator nucleotides enables extension of the 
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third primer specifically to the polymorphic or mutation site 
and generates allele-specific extension products from wild-
type and mutant DNA (fig. 1). Unspecific amplified PCR 
products cannot serve as a template in the extension reaction. 
Each extension product has a unique molecular mass, result-
ing in separated signals analysed by MALDI-TOF MS through 
the mass/charge ratio to differentiate between alleles differing 
by as little as one base robustly [45]. Less than 5% mutant 
DNA in a more than 95% wild-type DNA background could 
be precisely discriminated [46]. Recently, multiplexing PCR 
and extension reactions in a single well with high automation 
is available to increase the high-throughput capacity and re-


Fig. 1. MALDI-
TOF MS in NIPD for 
monogenic disorders. 
A Two forms of auto-
somal inheritance in 
monogenic disorders. 
B Two methods: 
hME and SABER. 
C MALDI-TOF-MS 
Compact System.  
D Allele specific 
extension products 
(mutant and/or wild-
type) detected by 
MALDI-TOF MS.
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duce cost for genotyping [47]. The high-throughput sensitive 
MALDI-TOF MS has been successfully used for detecting 
fetal single nucleotide mutations in maternal wild-type DNA 
allowing for NIPD of genetic diseases [48, 49]. For NIPD, to 
increase the sensitivity of detection of minority fetal DNA in 
majority maternal DNA molecules, Ding et al. [48] modified 
the hME protocol and developed a single allele base exten-
sion reaction (SABER) followed by analysis by MALDI-TOF 
MS. Compared to the hME, which involves base extension of 
both mutant and wild-type alleles, SABER extends only fetal-
specific mutant alleles [49, 50]. 
MALDI-TOF MS in Non-Invasive Prenatal Diagnosis for 
Monogenic Disorders Using cff-DNA
Figure 1A illustrates the strategies of NIPD for the two forms 
of inherited disorders – autosomal dominant and autosomal 
recessive inheritances. 
Autosomal dominant paternally inherited genetic traits 
absent in the maternal genome can be examined for NIPD 
using cff-DNA in maternal circulation. For the autosomal 
dominant inheritance, if a father is affected, the NIPD can 
be applied to identify all of his offspring either affected with 
presence of paternally inherited mutation or unaffected with 
absence of paternally inherited mutation in maternal circu-
lation. Achondroplasia is a type of autosomal dominant ge-
netic disorder [51]. An autosomal dominant mutation in the 
fibroblast growth factor receptor gene 3 (FGFR3) causes 
an abnormality of cartilage formation and leads to several 
shortened bones [52]. In our group, two couples were en-
rolled for NIPD of achondroplasia. Using MALDI-TOF 
with SABER, the fetal mutation on FGFR3 was detected 
in maternal circulation in the two affected cases [53]. The 
successful NIDP gave the parents the chance to prepare for 
their babies being short-limbed dwarfism. Since cff-DNA 
sequences in maternal circulation are smaller than mater-
nal ones, the selection of small cff-DNA fragments by size 
fractionation by agarose gel electrophoresis leads to the en-
richment of cff-DNA sequences. In our study for NIPD of 
achondroplasia, Li et al. [53] compared the MALDI-TOF 
MS approach with and without size fractionation performed 
before the PCR. The size fractionation gave a stronger sig-
nal for the fetal allele. 
For NIPD of autosomal recessive inherited genetic traits, 
a strategy has been developed to exclude the compound het-
erozygous conditions through the detection of cff-DNA in ma-
ternal plasma [54]. An affected fetus with a compound hetero-
zygous condition harbours two different mutations, one from 
the father and another one from the mother (fig. 1A). An ab-
sence of a paternal mutant allele or presence of paternal wild-
type allele in maternal plasma indicates that the fetus has not 
inherited the mutated paternal allele and thus cannot manifest 
such disorder [55, 56]. 
Thalassaemias are types of autosomal recessive hereditary 
anaemias due to defects in haemoglobin production caused 
mainly by mutations. More than 300,000 infants with major 
thalassaemias are born every year, and it is associated with 
considerable morbidity and mortality. The WHO declares 
these disorders a major public health problem worldwide. As 
an important step in the prevention of severe β-thalassaemia, 
the prenatal detection of homozygous and compound hetero-
zygous pregnancies is used [57–59]. 
More than 200 β-thalassaemia mutations have been report-
ed [60]. Ding et al. [49] evaluated the use of MALDI-TOF MS 
with hME and SABER for the discrimination of fetal point 
mutations in maternal plasma to develop a NIPD for the ex-
clusion of thalassaemia major in four most common β-thalas-
saemia mutations in Southeast Asia: CD 41/42 -CTTT, IVS2 
654 (C 3 T), nt -28 (A → G), and CD 17 (A → T). Eleven 
pregnancies between 7 and 21 weeks of gestation at risk for β-
thalassaemia major, in which the involved father and mother 
carried different β-thalassaemia mutations, were recruited for 
the exclusion of fetuses with compound heterozygous. Six out 
of 11 cases showed the absence of the paternal mutant allele 
in maternal circulation, suggesting that the babies do not man-
ifest the thalassaemia major. Detection of the paternal muta-
tion in maternal plasma by using the SABER protocol was 
completely concordant with the fetal genotype determined by 
invasive prenatal diagnosis, whereas the hME protocol gave 
two false-negative results, implying that the SABER protocol 
seemed to be more sensitive than the hME protocol. 
For NIPD of the thalassaemia major, in our group, we first 
developed a simple, fast and cost-effective allele-specific real-
time PCR to detect the presence of the paternal mutant fetal 
allele in maternal circulation. Four common β-thalassaemia 
mutations in the Mediterranean region, IVSI-1, IVSI-6, IVSI-
110 and codon 39, were analysed in the study. Cff-DNA was 
enriched by size fractionation on gel electrophoresis to en-
hance the sensitivity of the approach, and a peptide-nucleic-
acid clamp, which was designed to suppress amplification of 
the normal maternal allele, was used to increase the specifi-
city of the PCR reaction. An overall sensitivity of 100% and 
a specificity of 93.8% in the samples with sufficient amount 
and quality of DNA could be achieved in a cohort study of 32 
cases [40]. Recently, we built an international network based 
on high-throughput of MALDI-TOF MS to evaluate the use 
of the system for NIPD in β-thalassaemia. The preliminary 
data shows the feasibility for the exclusion of thalassaemia 
major in 6 most common β-thalassaemia mutations, IVS1-1, 
IVS1-6, IVS1-110, IVS2-745, CD39 and CD44, in the Mediter-
ranean region (data not shown). 
X-linked diseases are also single gene disorders caused by 
mutations on the X chromosome. In X-linked recessive con-
ditions, e.g. red-green colour blindness, haemophilia and the 
Duchenne and Becker forms of muscular dystrophy, a nor-
mal female carrier passes mutations on an X chromosome to 
50% of her daughters normally being a carrier and to 50% 
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of her sons being affected. The strategy of prenatal diagnosis 
of X-linked recessive conditions is to exclude the female off-
spring from the risk of the disease. Identification of fetal gen-
der regarding prenatal diagnosis for X-linked disorders can 
be performed by ultrasonography, which is available from 14 
weeks of gestation. However, fetal SRY, which is Y-chromo-
some-specific and absent in the maternal genome, is detect-
able in maternal plasma from the 5th gestational week using 
standardized simple and robust real-time PCR. The approach 
has been successfully translated to clinical routine applica-
tion. An alternative NIPD of fetal gender can be performed 
using MALDI-TOF MS. Ding et al. [48] evaluated the use of 
MALDI-TOF MS to detect fetal SRY in maternal plasma. 
When the input DNA containing more than one copy of SRY 
per reaction, a 100% accuracy could be achieved to identify 
fetal gender using the MS approach. 
MALDI-TOF in NIPD of Fetal Blood Group Genotyping
The Rh blood group system contains 5 main Rh antigens (C, 
c, D, E and e) on the surface of human red blood cells. RhD 
is the most important antigen causing haemolytic disease of 
newborn (HDN) in pregnancies. A routine antenatal anti-
D prophylaxis for RhD-negative pregnant women has been 
recommended; however, this immunoprophylaxis is cost-con-
suming and has risks associated with administration of blood 
products, possibly resulting in viral infection [61–63]. If a 
partner of an RhD-negative pregnant woman is RhD-positive 
heterozygous, 50% of their offspring will be RhD-negative 
and will be at no risk for immunization. Therefore, the health 
service is unnecessary for those cases. IPD for identification 
of fetal RhD status, with the aim of managing RhD-negative 
pregnant women, might lead to miscarriage and immunization 
[64–66]. The NIPD of the fetal RhD status using cff-DNA 
in maternal blood by real-time PCR is well established and 
already offered as a clinical service in a number of countries 
[67]. A gold standard for diagnosis can be achieved [68]. In 
our group, we also evaluated the feasibility of using MALDI-
TOF MS to detect fetal RhD sequence in maternal circulation 
from RhD-negative pregnant women [69]. Primers were de-
signed to amplify fetal RhD exon 7. The presence or absence 
of the fetal RhD exon 7 was determined by MALDI-TOF MS. 
With SABER protocol, we were able to detect 15 pg of RhD-
positive genomic DNA in a background of 585 pg of RhD-
negative genomic DNA corresponding to the concentration of 
cff-DNA in maternal plasma. A total of 178 plasma samples 
from pregnant women were analysed in a blinded manner 
by the approach. A sensitivity of 96.1% and a specificity of 
96.1% could be achieved, which is comparable with those by 
quantitative real-time PCR [69]. However, the MALDI-TOF 
MS promises high-throughput detections of up to 384 samples 
per single chip, which can be applied for large-scale analysis. 
In addition, the multiplexing PCR and extension reactions in 
a single well with high automation offers the possibility to de-
tect variant Rh alleles, to increase the high-throughput capac-
ity, and to reduce cost for blood group genotyping.
The Kell blood system is defined by a group of antigens on 
the surface of human red blood cells. KEL1 and KEL2 are 
the most common alleles in the Kell blood system based on 
a single base substitution (C to T) in exon 6 of the Kell gene 
[70, 71]. The KEL1 antigen, found in 9% of Caucasians, is the 
second most important antigen causing HDN in pregnancies 
[72, 73]. We developed the MALDI-TOF MS-based SABER 
to examine the fetal KEL1 gene from 32 KEL1-negative preg-
nant women with a median gestation of 21 weeks using cff-
DNA in maternal plasma. The extension primer was designed 
only for extending the mutant allele T site from the fetus. 
After PCR amplification and SABER procedure, following 
MALDI-TOF MS analysis, we were able to detect the fetal 
KEL1 allele in 11 of the 13 KEL1-positive samples. No false-
positive results were scored. The paternal KEL1 allele could 
be correctly determined in 94% of cases (30/32) [74]. 
Human platelet antigens (HPAs) are associated with im-
mune-mediated platelet disorders [75, 76]. 24 HPAs have been 
defined by serology 12 of which are grouped in 6 biallelic sys-
tems (HPA-1, HPA-2, HPA-3, HPA-4, HPA-5 and HPA-15) 
followed by either an ‘a’ for the more common allele or a ‘b’ 
for the less common allele [77]. The most well-known alloim-
mune thromboembolic disease is neonatal alloimmune throm-
bocytopenia (NATP), which is caused by passively transmit-
ted maternal antibodies specific against paternally inherited 
fetal HPAs [78, 79]. The NATP is caused by fetomaternal 
mismatches of HPA-1 and HPA-5 in Caucasians and HPA-3 
and HPA-4 in Asians [80, 81]. In our group, we developed a 
multiplexed assay using MALDI-TOF MS for simultaneously 
genotyping 6 HPAs and 12 alleles (HPA-1a/1b, HPA-2a/2b, 
HPA-3a/3b, HPA-4a/4b, HPA-5a/5b and HPA-15a/15b) in 
a single tube. We examined 120 donors by the multiplexed 
assay and compared the results generated by a sequence-spe-
cific primer PCR (SSP-PCR) and conventional sequencing. A 
99.7–100% concordance for the genotyping of the 12 HPA al-
leles between the MALDI-TOF MS assay and conventional 
methods was achieved [47]. The multiplexed assay allows for 
the elimination of the time- and cost-consuming gel electro-
phoresis or fluorescent labelling. Our data suggests that this 
precise approach using cff-DNA may apply to NIPD for HPA 
genotyping regarding NATP. 
MALDI-TOF MS in Prenatal Diagnosis of Chromosomal 
Aneuploidy
hME-based MALDI-TOF MS can be used to analyse copy 
number variation of each allele [45, 82, 83]. An allele-specific 
primer extension reaction designed by the hME to a hetero-
zygous SNP generates two extension products, each has 
unique molecular weight, resulting in 2 peaks on MALDI-
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TOF MS. For every heterozygous SNP site, the intensity 
of the pair of mass signals are recorded and interpreted by 
MassARRAY® software (Sequenom). The relative quantifi-
cation of copy number can be estimated through dividing the 
peak intensity generated from one allele by that of another 
allele. The ratios between two alleles are obtained as quantifi-
cation of copy number variation. This concept can be applied 
for the detection of abnormalities in chromosome number. 
First, the company Sequenom investigated the feasibility of 
the concept to measure the allelic ratio of the chromosome 
21 SNPs to identify trisomy 21 for prenatal diagnosis using 
the fetal genetic materials obtained by an invasive procedure. 
Heterozygous SNPs within the Down syndrome-critical region 
(DSCR) of chromosome 21 were selected for determining the 
chromosome ratios. The presence of a third copy could be 
identified by a deviation from the expected 1:1 allelic ratio in 
a euploid fetus as a 2:1 or a 1:2 ratio in trisomic fetus. Multi-
plex assays for a combination of 12 SNPs located within the 
region were performed on individuals of African, Asian, Eu-
ropean, and Hispanic origin to analyse Down syndrome cell 
lines and chorionic villus samples containing trisomy 21 cases. 
An accuracy of 95% for discriminating trisomic and euploid 
DNA samples could be achieved by the preliminary study 
[84]. Subsequently, Tsui et al. [85] evaluated the use of the ap-
proach to identify trisomy 21 in various clinical samples, such 
as placenta, amniotic fluid and chorionic villus samples from 
normal and trisomy 21 cases. With no false-positive or false-
negative results using more ‘user-friendly’ assays, the group 
recommended the approach as an alternative tool for prena-
tal diagnosis of trisomy 21; the approach is faster and more 
simple, and it has a high-throughput capacity compared to the 
conventional methods. To apply the approach for clinical use, 
our group performed a large-scale study on a cohort with 350 
subjects [86]. Again, our data suggested that MALDI-TOF 
MS is a robust and reproducible method for the detection of 
trisomy 21. In addition, we could also show that cff-DNA in 
amniotic fluid supernatants were useable to the identification. 
The only disadvantage compared with fluorescent in situ hy-
bridization (FISH) and karyotyping was that the system could 
not promise the identification of a mosaic case [87]. 
The concept of measuring copy number variation within 
chromosome 21 for prenatal diagnosis of trisomy 21 using in-
vasively obtained fetal genetic materials has been extended 
for developing NIPD using cell-free fetal genetic materials 
in maternal circulation in a risk-free application. Placenta-
specific 4 (PLAC4) is expressed specifically in the placenta. 
The placenta-specific mRNA is transcribed from a gene lo-
cated on chromosome 21. Placenta-derived PLAC4 can pass 
through the placenta and be released into maternal circula-
tion. Molecular biological techniques allow precise quantifi-
cation of PLAC4, which is absent in adult blood, in mater-
nal circulation during pregnancy. Lo et al. [88] developed a 
RNA-SNP allelic ratio approach to determine the dosage of 
chromosome 21 using PLAC4 mRNA in maternal plasma 

Fig. 2. MALDI-TOF MS in NIPD for aneu-
ploidy using RNA-SNP. A Selection of a tran-
scribed SNP locus on the chromosome of inter-
est. B Selection of a placental specific mRNA. 
C RNA-SNP specific extension products ana-
lysed by MALDI-TOF MS.
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(fig. 2). Heterozygous SNPs present in the coding region of 
the PLAC4 gene can be selected for this purpose. The pres-
ence of a third copy of chromosome 21 containing a hetero-
zygous SNP could be identified by a deviation from the ex-
pected 1:1 ratio of PLAC4-SNP in a euploid fetus as a 2:1 
or a 1:2 ratio in trisomic fetus. Using the MALDI-TOF MS, 
the RNA-SNP allelic ratio could be measured precisely for 
NIPD of trisomies. The approach was applied to maternal 
plasma analysis in 57 women carrying karyotypically normal 
fetuses with a mean gestation of 13 weeks and 10 women car-
rying trisomy-21 fetuses with a mean gestation of 14.7 weeks. 
A diagnostic sensitivity and specificity for trisomy 21 of 90 
and 96.5% respectively could be achieved by the group [88]. 
This strategy could also be applied to trisomy 18 and 13 [89]. 
However, the limitation of this approach is that the diagno-
sis can only be performed for the pregnant women carrying 
fetuses containing heterozygous SNPs on coding regions 
of genes of interest. In addition, before processing the ap-
proach, informative heterozygous SNPs in the fetus should 
be obtained [88]. 
MALDI-TOF MS in Identifying Fetal Gender- 
Independent Circulating Biomarkers
Cff-DNA in maternal blood is associated with alteration of 
placental shedding. Elevated levels of cff-DNA in maternal 
circulation are seen with pathological pregnancies due to the 
increased cell turnover and/or impaired clearance [90, 91]. In 
preeclampsia, cff-DNA increased prior to its onset, and the 
levels corresponded to its severity, suggesting a protective 
diagnostic value for earlier diagnosis as well as for tailoring 
management of the patients [92–94]. In preterm labour, the 
levels of cff-DNA in maternal circulation could be used to 
distinguish between falsely and truly affected cases [95]. The 
results reveal the significance of transition from research find-
ings to clinical practice. However, cff-DNA-based, non-inva-
sive prenatal applications are limited by the lack of gender-
independent fetal-specific genetic markers that would allow 
monitoring of all pregnancies [96]. Recently, a placenta-spe-
cific methylation profile has been suggested to serve as fetal 
gender-independent placental DNA marker to distinguish 
between fetal and maternal DNA in maternal circulation [97]. 
However, the use of this concept has been limited by the fact 
that no technique or general approach is superior for robust 
quantitative and sensitive analysis of methylation status [98, 
99]. Sequenom’s EpiTYPER™ assay created the opportu-
nity for high-throughput quantitative analysis of DNA meth-
ylation status using MALDI-TOF MS with MassCLEAVE™ 
reagent, which is based on base-specific (C/T) cleavage reac-
tions [100, 101]. The robustness of the approach for quantify-
ing methylated and unmethylated DNA has been evaluated 
by Sequenom [102] and also by our group [103]. The system 
enables combining quantitative, sensitive, automated, and 
high-throughput detection of methylation status in a single 
technique. Base-specific (C/T) cleavage reactions generate a 
cleaved CpG site, and the intensity of a pair of mass signals, 
one representing methylated and/or another one represent-
ing unmethylated DNA, can be recorded and interpreted by 
MassARRAY EpiTYPER software. The relative quantifica-
tion of the methylation status can be estimated through divid-
ing the peak intensity, or area of the methylated DNA, by the 
sum of the intensities or areas of the methylated and unmethyl-
ated components. The ratios between methylated and un-
methylated DNA are obtained as quantification of methyla-
tion. In our group, we mixed fully methylated DNA into the 
pure unmethylated DNA in different ratios of 100:0, 50:50, 
25:75, 5:95, and 0:100. The assay was able to discriminate the 
5% methylated in 95% unmethylated components according 
to the ratios by the quantitative assay [103]. As little as 5 ng 
of DNA per PCR reaction could guarantee the methylation 
analysis using the system. The approach may be applicable to 
develop methylation-based fetal gender-independent placen-
tal markers for NIPD. 
SNPs occur in the genome frequently, with an average of 
one SNP found per kilobase. Paternally inherited SNPs, which 
can be robustly identified by primer extension reaction-based 
MALDI-TOF MS, may be useful to develop fetal gender-in-
dependent markers. In our group, we tested 41 SNP loci in 
18 maternal plasma samples, 10 taken at term and 8 obtained 
early in the second trimester, using hME- and SABER-based 
MALDI-TOF MS combined with size fractionation. Ten pa-
ternally SNPs, rs1009789, rs109889, rs13234721, rs231146, 
rs30207, rs323421, rs405120, rs4778, rs547363 and rs776008, 
allowed us to distinguish between fetal and maternal cf-DNA 
for the 10 samples taken at term. The other eleven SNPs, 
rs109889, rs1475840, rs170183, rs2003624, rs222775, rs2835349, 
rs30207, rs375579, rs432137, rs732569 and rs776008, have been 
successfully used for detecting minority fetal in majority ma-
ternal components in the 8 samples obtained in the second 
trimester [49]. 
Conclusion
MALDI-TOF MS is completely automated for high-through-
put analysis of as much as 384 samples running on one silicon 
chip. Developments of different protocols and assays enabled 
robust genotyping of single base difference, precise measur-
ing of copy number variation, and quantitative methylation 
and expression analysis. Compared with conventional meth-
ods, the higher sensitivity of this approach offered opportuni-
ties for NIPD dealing with fetal genetic materials as minority 
mixed into maternal background molecules as majority. The 
high degree of multiplexing in one reaction makes the system 
cost-effective, fast, simple, and user friendly. However, the 
sophisticated and expensive equipment is recently not readily 
available to the majority of diagnostic or research laborato-
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ries. A single chip fixed with a curtain format for evaluating 
up to 384 samples makes single case detection, which is often 
seen in prenatal diagnosis, inflexible. In addition, NIPD of au-
tosomal recessive homozygous disease as well as clinical ap-
plication of NIPD for aneuploidies still remain considerably 
challenging. 
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